Similares a Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD

20 vecinos (text_768) · 198 views · HCPLive · Estados Unidos


★	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos
3	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	88
18	Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026	HCPLive @hcplivenews	548	Estados Unidos	85
14	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	85
13	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	85
20	Sotatercept May Improve Right Heart Function in #pulmonaryhypertension	HCPLive @hcplivenews	232	Estados Unidos	84
8	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	156	Estados Unidos	86
16	What the Phase 3 AD109 Data Mean for Sleep Apnea, With Patrick John Strollo, MD	HCPLive @hcplivenews	142	Estados Unidos	85
6	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	87
5	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	87
19	Sotatercept May Improve RV Function in Group 3 3 Pulmonary Hypertension	HCPLive @hcplivenews	112	Estados Unidos	84
1	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	97
12	Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD	HCPLive @hcplivenews	88	Estados Unidos	85
7	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	82	Estados Unidos	86
10	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	86
11	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	85
15	Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More \| EAC 2026	HCPLive @hcplivenews	58	Estados Unidos	85
2	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	89
17	Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients	HCPLive @hcplivenews	53	Estados Unidos	85
4	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	88
9	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	86